Main Text
How does a cell in an organism differentiate signals from noise while being immersed in bath of growth factors and hormones? This issue is one of the major challenges in understanding how the high fidelity and specificity of biological responses are generated. Engineers have considered similar problems for a long time. Can we borrow concepts from engineering to understand biology?
In the early 20 th century, the reliable transmission of telephone signals became a growing problem as lines became longer. To transmit signals over longer distances, amplification was needed, but noise and distortion were added every time the signal was amplified. A solution to this problem was the negative feedback amplifier (NFA), an invention made in 1927 by Harold Stephen Black, an employee of Bell Laboratories, who proposed that the output of the amplifier be used to attenuate its input, creating a negative feedback loop 2 . This proposal seemed so counterproductive that it took 9
years for a patent to be issued. Why would one want to decrease the magnitude of a signal that needs to be amplified? There are actually two good reasons for doing this. First, consider the effects of signal amplification on the dynamic range of the transduction system. With higher amplification (gain), the output will be saturated at lower input magnitudes, reducing the dynamic range. However, with negative feedback in place, the amplification is diminished, thus allowing the output to respond to a greater range of input magnitudes, in a more linear fashion. Second, consider that during signal transmission, there is a perturbation to the amplifier, such that its output magnitude is now suddenly too high. With a negative feedback loop in place, this increased magnitude is passed back to the amplifier input as increased negative feedback strength, consequently attenuating the input signal and mitigating the effects of the perturbation. Thus, although the amplifier gain is reduced by the negative feedback, the NFA affords increased resistance to perturbations within the amplifier and a greater range of responsiveness to different input strengths. These properties seem very useful for biological signaling networks that constantly have to deal with intrinsic and extrinsic noise while simultaneously responding to a sea of varied-concentration growth factors. And what are the implications for biology and medicine?
MAPK cascades as signal amplifiers
Mitogen-activated protein kinase (MAPK) cascades are conserved from yeast to mammals.
Although originally discovered as kinases that are activated by mitogens, the acronym has become the name for a large family of kinases that respond to different signals including hormones, stress, radiation and mechanical cues 3, 4 . They share a common topology with a three-tiered module of kinases at the core. [17] [18] [19] . This is because only a percentage of total Ras is at the plasma membrane, where it can be activated by receptors, and then only a fraction of the correctly localised Ras will become activated. The number of ERK1/2 molecules that become activated (ppERK) in response to Ras activation, however, is much higher. Approximately 50% of the total 60,000 to 100,000 ERK1/2 molecules per cell become active in response to typical EGF doses 20, 21 , and even more than 50% in many instances as estimated from gel shift assays 22, 23 . A main reason for this signal amplification is that under many conditions, at each tier of the cascade the signal will be amplified. Thus, in many situations the sensitivity of the final output (ppERK) to the initial input (RasGTP) increases multiplicatively when a tier is added 24, 25 . This sensitivity amplification was demonstrated experimentally in Xenopus oocytes, where the Hill coefficient (which quantifies the steepness of a sigmoidal input/output response, i.e. the sensitivity) is greater for a three-tiered cascade than for a two-tiered cascade 26 . The multi-site phosphorylation mechanism operating within the kinase module adds further to this sensitivity amplification, if the phosphorylations occur in a distributive manner, where each phosphorylation involves separate kinase and substrate binding and dissociation events, rather than in a processive manner, where kinase and substrate do not dissociate after the first 6 phosphorylation event 27, 28 . It has been shown in vitro that the activation of ERK by MEK 29 and deactivation of ERK by MAPK phosphatase 3 follow a distributive mechanism 30 . Recent work shows that both mono-and bi-phosphorylated forms of ERK are observable after Epo stimulation in primary erythroid progenitor cells 31 , implying that either ERK phosphorylation or dephosphorylation may be distributed in vivo. However, it will be interesting to examine this issue in different cell types as the organisation of the cascade by scaffolding proteins 32, 33 may convert the distributive mechanism into an apparent processive one.
While the cascade structure of MAPK pathways allows for amplification of signals, it comes at an inevitable tradeoff: with higher amplification comes a shorter linear range of input doses to which the system output will respond 13, 34 . Also, amplification, as discussed here, does not take into account system dynamics, which are thought to be important for physiological effects elicited by MAPK signalling pathways 10, 11, 35, 36 . How do cells control MAPK dynamics and respond to large ranges of input doses? One answer to this question is by negative feedback.
Negative feedback: modulating input/output sensitivity, tuning dynamics, and conferring robustness to perturbations
On top of the core ERK1/2 pathway lays a plethora of negative feedback loops that span multiple time scales (Fig. 2) . The light blue lines in Fig. 2 denote short-term negative feedback loops, which begin to act nearly immediately upon activation of ERK. Activated ERK leads to the phosphorylation and inactivation of the RasGEF SOS 37, 38 , and modelling suggests that several phosphorylation sites on SOS all independently mediate strong negative feedback 39 . This would afford a simple mechanism for a dosage dependent negative feedback. Gab1, a scaffolding protein involved in PI-3K and RasGEF recruitment to the plasma membrane, is also inhibited by ERKdependent phosphorylation 40 . In addition, Raf-1 is phosphorylated and inhibited by ERK 1, 41 , and this is one of the strongest negative feedbacks in mouse fibroblasts 42 . from engineering have several properties that were reproduced experimentally using this setup. First, according to theory, when negative feedback is present, the relationship between system output and input becomes more linear, countering the effects of multiple kinase tiers and multi-site phosphorylation to amplify input/output sensitivity. Experimentally, when the ERK pathway was activated by increasing serum levels, the ppERK levels increased smoothly, in a linear fashion.
However, when the ERK pathway was stimulated by increasing tamoxifen levels, ppERK levels increased sharply, with bimodal cell population responses. Thus, negative feedback makes the ERK response more linear with respect to increasing input magnitude. Second, again according to theory, negative feedback should make the system robust to perturbations within the feedback loop, but not against perturbations outside of it. Experimentally, when the ERK pathway was stimulated with EGF, ppERK levels were resistant to the effects of MEK inhibition (using the specific chemical inhibitor U0126), much more than when the pathway was stimulated with tamoxifen. These results show that the negative feedback indeed confers robustness towards perturbations to the amplifying module.
However, inhibition of the EGFR (by 4557W) yielded a more linear, dose-dependent inhibition.
Interestingly, this linear inhibition occurred despite the negative feedback from ERK to the EGFR. As the EGFR is outside of the amplifier module, these results suggest that the NFA effect depends on the combination of an amplifier with negative feedback. Alternatively, this might also mean that the strongest negative feedbacks lie downstream of the EGFR, as was indeed found to be the case in mouse fibroblasts 42 . In a more general sense these results indicate that the engineered NFA design captures the essence of the biological design of the ERK pathway. This then predicts that other salient
properties of the engineered NFA should apply to the biological NFA.
A salient NFA property is that despite the reduced gain, it still will linearly amplify signals 2 .
Therefore, the ERK cascade should behave as a linear amplifier. In fact, linear increases in RasGTP after stimulation with growth factors correspond to linear increases in ppERK in different cell lines 19, 60, 61 . However, the relationship between growth factor dose and ppERK is generally log-linear, with ten-fold increases in growth factor dose leading to linear increases in ppERK 10 
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Here, L 50 is the ligand dose eliciting half-maximal receptor activation responses, R * max is the maximum level of ligand-bound (active) receptors, and n is the cooperativity coefficient (n<1 means negative cooperativity). In some cases, there is a linear relationship between the levels of active (tyrosine phosphorylated) receptor and ppERK levels 47, 60 . In such cases, R* may be taken as a surrogate for ppERK levels. It was reported that n=0.31 for EGF binding to EGFR 63 , and plotting Eq.
1 with this value of n indeed gives a log-linear relationship between ligand dose and active receptor levels spanning approximately five decades (Fig. 3) . Amazingly, this corresponds quite closely to the dose-response characteristics of EGF-stimulated ERK activation in several cell lines, where limit of detection occurs between 10 -3 to 10 -2 nM EGF stimulation, and saturation occurs around 10 nM EGF, with log-linear increases between [e.g. 47, 62 , MRB personal observations]. Thus, negative cooperativity of ligand-receptor binding may provide a simple yet effective mechanism for making cells respondent to a wide range of growth factor concentrations, which would work in synergy with the downstream negative feedback amplifier system to transduce these signals reliably. If this is the case, then one might expect similar behavior from other growth factor receptor systems. Indeed, negative cooperativity in ligand-receptor binding is observed for platelet derived growth factor type BB 64 , insulin 65 66 , and insulin-like growth factor 66 .
Strong negative feedback combined with a time-delay and strong stimulation can lead to oscillatory behaviour. 67 The long-term negative feedbacks clearly have a significant time delay.
Although many of the short-term feedbacks result from direct feedback phosphorylation from ERK and therefore have small time-delays, some are only dependent on ERK activity, and most likely are mediated by downstream kinases such as the RSKs 68 . Nevertheless, even the negative feedbacks involving direct ERK phosphorylation take time to travel from the substrate and through the pathway back to ERK, introducing some time-delay. A strong stimulation causes rapid and large activation of ERK, which, with a time-delay, causes strong negative feedback. This not only causes ERK activity to go back down but also the negative feedback, which then leads to increasing ERK activity, albeit not to levels as high as the original stimulation, as there is now negative feedback present. 70, 71 . As primarily only activated ppERK is translocated to the nucleus, these results imply sustained oscillations in ppERK levels.
Another function of negative feedback is adaption, i.e. return of activity to near pre-stimulus levels despite the persistence of stimulus 72 . This is also referred to as "transient" signalling, which is the topic of much study as whether ERK signalling is transient or sustained in response to growth factors is thought to play a major role in cell-fate decisions 11 . In general, the stronger the negative feedback, the nearer Ras and ERK activity return to pre-stimulus levels. However, strong and fast negative feedback also reduces the peak signalling amplitude before adaption is complete, so some time delay is desirable. Since, as discussed above, too much time delay can lead to oscillations, there is a fine balance the strength and dynamics of the negative feedback and the system behaviour. Which of the negative feedback(s) are responsible for transient signalling and adaptation is still largely unclear.
When ERK itself is responsible for direct negative feedback by phosphorylation, then the system will not exhibit perfect adaption, where Ras and ERK activity return exactly to pre-stimulus levels. 72 . A perfect adaptive behaviour is characteristic of an engineering design termed "integral negative feedback", where the strength of the negative feedback is proportional to the time-integrated forward activity. Recent modelling work suggests that the long-term, transcriptional negative feedbacks might act as such integral negative feedback circuits, as mRNA responses of active ERKdependent gene transcription are proportional to the total time active ERK spends in the nucleus 10 .
Thus, a distinguishing function of the long-term negative feedback versus the short-term negative 12 feedbacks may be perfect adaptation. Such feedbacks, however, can be saturated by oncogenic insults.
For instance, DUSP6 expression induced by constitutively active Ras is unable to bring about adaptation of ppERK levels 73 .
Part and parcel with adaption comes desensitization, or the ability of ERK pathway activity not only to return to pre-stimulus levels (adaptation), but also to reduce its sensitivity to subsequent changes in stimulus levels, despite the persistence of the stimulus. Expression of the various transcriptional negative feedback regulators, DUSPs, Mig6 and Sprouty, may help to accomplish desensitization, allowing ERK activity to respond similarly to a wide range of input strengths. This also may be controlled at the receptor level by changes in receptor trafficking and cell surface availability 74 , and also, as discussed above, may be partly an inherent property of receptors with negative cooperativity in ligand binding. However, very little MAPK modelling work to date has been focused on desensitization, so it is unclear precisely how the various negative feedback mechanisms coupled with receptor trafficking and ligand binding may play a role.
Outlook for medicine: fighting against the negative feedback amplifier
Given the multitude of strong negative feedbacks operating in many different cell types, treatment strategies focused on inhibiting entities within such feedback loops is most likely unavoidable. In fact, in breast cancer cell lines, feedback strength from the ERK1/2 pathway seems to determine whether or not the cells are susceptible to MEK inhibition 58 . This is natural, however, as
Sturm and coworkers have shown that the output activity of such negative feedback amplifier systems is resistant to inhibition within the system 1 . By using a mathematical model of the ERK pathway, an elegant yet simplistic approach to fighting the negative feedback amplifier was derived. The partial inhibition of the negative feedback by using a Raf inhibitor weakened the negative feedback effects enough to allow a MEK inhibitor to function optimally 1 . From a biological standpoint, doing such an experiment is counterintuitive. As the inhibitors target two sequential components in a linear pathway,
by common biological sense they should have the same effects. However, the results of this experiment showed that biological intuition is a poor tool to grasp biological properties emerging 13 from design. A small amount of Raf inhibitor that insignificantly affected ppERK1/2 levels caused an order of magnitude increase in the sensitivity of ppERK1/2 levels to a MEK inhibitor. 1 Thus, applying mathematical modelling to analyse emergent properties arising from the design of signalling pathways may go a long way to explain unexpected phenomena. More importantly, the predictions originating from the models can help to design experiments probing the implications of the design structure of signalling pathways. More importantly, such predictions can explain drug failures and appropriate remedies. We envision that in the future such approaches will help to discover new drug targets rationally, and also to use our current drug repertoire in a more intelligent and effective manner. 
